Frontlight ResearchEarly access
Neuroendocrine tumours trials in Hong Kong
1 trial · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Hong Kong
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00